Aya Mohamed | MSc, MD 🎗· @Dr_Oncologista · X·· 2 days agoScore70
Body · original
Honored to be part of this discussion with OncoDaily and esteemed colleagues on the 6-year NATALEE data and its implications for breast cancer care.
#ESMO26 #BreastCancer @OncoAlert
#ESMOAmbassadors #ESMOcommunity @myESMO
265 views · 11 likes · 3 reposts · 3 replies
Conference abstracts
LBA25matched by Proffered paper 1: Breast cancer, early and advanced stage
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.orgOncologists Discuss NATALEE Trial The six-year #NATALEE trial results presented at #ESMO2026 showed an overall survival benefit and sustained improvements in invasive disease-free survival with adjuvant ribociclib plus endocrine therapy in patients with HR+/HER2− early breast cancer. https://oncodaily.com/science/natalee-esmo-26-615553 @KefahMokbel @SuyogCancer @emadshash @Timothee_MD @DrBarbiOnc @HundalJasmin @Aydah_AlAwadhi @DrSGraff @dr_yakupergun @kazuki_nozawa @sara_soliman7 @stolaney1 @Dr_Oncologista @DrHBurstein在 X 查看被引用的帖子
Replies in this thread
- Aya Mohamed | MSc, MD 🎗@Dr_Oncologista
@Oncologist_ch @OncoAlert @myESMO Many thanks, dear! ❤❤
- Aya Mohamed | MSc, MD 🎗@Dr_Oncologista
@hager_sa3iid @OncoAlert @myESMO Thanks a lot sweetie 😍
- Christine Michel@Oncologist_ch
@Dr_Oncologista @OncoAlert @myESMO Keep shining! So proud of you and all you’re achieving! ❤️👏👏✨
Source: Aya Mohamed | MSc, MD 🎗 · x.com